Charles Wei
Assistant of President

Zhongyuan Union Cell & Gene Engineering Corp., Ltd.

Zhongyuan Union Cell & Gene Engineering Corporation, Ltd (Zhongyuan Union) is a leading and the only company focusing on cell and gene engineering technology in China, which is listed in the domestic stock market with code 600645. The company is one of the first companies investing biological resources storage and now dual drive by both cell and gene. Zhongyuan Union is also the deputy director of the National Strategic Alliance for Technical Innovation of Stem Cell and Regenerative Medicine Industry and has carried the project in building the national stem cell and gene clinical translational base. Meanwhile, it operates the Tianjin Cord Blood Bank, one of the large cord blood banks in the world.

After fifteen year successful development, Zhongyuan Union has operated four well-known affiliated companies, including Union Stem Cell & Gene Engineering Co., Ltd., Alliancells Bioscience Co., Ltd., Zhongyuan Union Gene Technology Co., Ltd and Shanghai Zhicheng Biological Technology Co., Ltd. At present, the Company owns biotech labs with more than 4000 square meters and its GMP standard production facilities. It has set up branch companies covering 23 provinces in China, provides the whole industrial chain products and services in cell and gene engineering. Its market value reaches 23 billion RMB.

The core technological and managerial team has more than 20 PhD and over 100 masters. Above 97% of the team has bachelor degree. Zhongyuan Union has also invited several world top scientists and scholars as the consultants of the technology committee, including:
‒ Sir Martin Evans, former chancellor of Cardiff University and the Nobel Prize Laureate in Physiology and Medicine in 2007
‒ Dr. Massimo Dominici, President of International Society for Cellular Therapy
‒ Prof. Wu Zuze, former chairman of Medical Science Academy of the PLA and Chinese Academy of Engineering Academician, known as “the founder of China stem cell therapy”
‒ Prof. Pei Gang, President of Tongji University, Academician of Chinese Academy of Sciences, President of Chinese Society of Cell Biology, Chief Editor of Cell Research
‒ Prof. Pei Xuetao, Director of Institute of Blood Transplantation Medicine, Academy of Military Medical Sciences
‒ Prof. Yu Jun, one of Founders of BGI, Former deputy president of Beijing Institute of Genomics, Chinese Academy of Science
‒ Prof. Xia Wenle, Director of Oncology Research Laboratory, Duke University Medical Center

The main advantages of the Zhongyuan Union:
 National Stem Cell Engineering Industrialized Base issued by China State Planning Commission since 2000
 National Research Center of Stem Cell Engineering issued by Chinese Ministry of Science and Technology since 2002
 National Cell Product Engineering Research Center issued by China Development & Reform Commission since 2004
 The deputy director of the National Strategic Alliance for Technical Innovation of Stem Cell and Regenerative Medicine Industry
 National Level Gene Detection Technique Platform
 The Consultant Team led by Nobel Prize Winners
 More than 90 national patents
 Undertaking many projects funded by "863 plan", "973 plan" and National Natural Science Foundation of China
 Cooperating with more than 80 3A-level domestic hospitals for the research on cell therapy for live diseases, neurological damages, immune system diseases and myocardial ischemia
 One of the largest cord blood banks with more than 300000 cord blood samples in storage

The main business of Zhongyuan Union:
 Cell banking (stem cell banking & immune cell banking)
 Gene testing & clinical diagnosis reagent
 Anti-aging products (makeup, healthcare product, )
 Tumor biotherapy
 Life bank service
 Zhongyuan Pharmacology
 Fund (M&A fund, public welfare fund for biological treatment, Venture capital fund)